MOTS-c Dosage Chart
Practitioner protocols for the mitochondrial-derived peptide MOTS-c, with the caveat that human safety and efficacy data are very early.
Educational tool — not medical advice. This calculator provides estimates based on population averages and published trial data. Outputs are not clinical recommendations and do not replace evaluation by a qualified prescriber. Do not start, stop, or change a peptide therapy based on the result of this tool.
MOTS-c is a mitochondrial-derived peptide encoded within the mitochondrial 12S rRNA gene. Preclinical work in animal models suggests roles in metabolic regulation, insulin sensitivity, and exercise response. Human data are very limited — a small number of pilot studies and observational data, no FDA approval, no large RCTs. Protocols are essentially research-experimental.
MOTS-c at a Glance
| Typical dose | 5–10 mg subQ |
|---|---|
| Frequency | 2–3× per week |
| Cycle length | 4–8 weeks on, 4 weeks off |
| FDA status | Not FDA-approved. Research-only. No human trial dosing label. |
| Source quality | Preclinical animal models + small human pilot data; protocols are practitioner-derived. |
MOTS-c Reconstitution Chart
How vial size, bacteriostatic water volume, and insulin-syringe units convert for MOTS-c. Use this to translate a prescribed mcg or mg dose into a syringe measurement.
| Vial size | Bac water | Concentration | Dose → insulin-syringe units (U-100) |
|---|---|---|---|
| 10 mg | 2 mL | 5 mg/mL (500 mcg per 0.1 mL) |
|
MOTS-c Dosing by Use Case
Commonly cited protocols vary by what MOTS-c is being used for. The table below summarizes typical ranges reported in clinical practice and published literature.
| Use case | Typical dose | Frequency | Cycle length | Notes |
|---|---|---|---|---|
| Metabolic / insulin sensitivity | 5–10 mg | 2–3× per week | 4–8 weeks | Practitioner-driven; not validated by human trials. |
MOTS-c has limited human safety data — frame use as experimental and time-limited.
- •Reported acute side effects in practice: minimal; injection-site reactions are the most common complaint.
- •Long-term safety in humans is essentially unstudied at consumer doses.
- •Theoretical: mitochondrial signaling effects are systemic — caution in patients with mitochondrial disease, autoimmune disease, or metabolic dysregulation.
- •Not FDA-approved.
- •Pregnancy or breastfeeding
- •Active mitochondrial disease (consult specialist)
MOTS-c Dosing FAQ
Animal data support roles in insulin sensitivity and metabolic homeostasis. Human evidence at consumer doses is preliminary — mostly small pilot studies and observational reports. We don't recommend treating MOTS-c as a validated metabolic therapy at this time.
There's no published safety or efficacy data on combining the two. Practitioner reports of co-administration exist; they are anecdotal.
Sources
Related Dosage Charts
Want the full MOTS-c guide?
Mechanism, clinical evidence, side effects, costs, and provider listings for MOTS-c therapy.
See MOTS-c guideMedical Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before beginning any peptide therapy treatment.